{"url_path":"/sec/indp/8-k/2026-05-15/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 ** **Results of Operations and Financial Condition.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1857044/0001493152-26-023344-index.html","accession_number":"0001493152-26-023344","cik":"0001857044","ticker":"INDP","issuer_name":"Indaptus Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1857044/0001493152-26-023344-index.html","primary_entity_key":"0001857044","primary_entity_name":"Indaptus Therapeutics, Inc."},"word_count":152,"has_tables":true,"body_markdown":"**Item 2.02.** **Results of Operations and Financial Condition.**\n\n \n\nOn\nMay 15, 2026, Indaptus Therapeutics, Inc. (the “*Company*”) issued a press release (the “*Press Release*”)\nannouncing its financial results for the quarter ended March 31, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this\nCurrent Report on Form 8-K.\n\n \n\nThe\nPress Release contains certain business updates and forward-looking statements regarding the Company’s expectations, plans and\nprospects. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes\nof Section 18 of the Securities Exchange Act of 1934, as amended (the “*Exchange Act*”), or otherwise subject to the\nliabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities\nAct of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}